Cat. No.: DAB-0012158
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Host Species | Mouse |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to human IGBP1. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | IGBP1 |
| UniProt No. | P78318 |
| Gene ID | 3476 |
| Gene Description | Immunoglobulin binding protein 1 interacts with the regulatory subunit C of serine/threonine phosphatase PP2A, and other protein phosphotases, PP4 and PP6. Binding of IGBP1 to PP2A has been shown to regulate PP2A catalytic activity and its substrate specificity. Recent evidence suggests that IGBP1 may play a role in PP2Ac ubiquitination via its association with E3 ubiquitin ligase MID1. IGBP1 negatively regulates apoptosis by targeting PP2A activity to suppress p38 mitogen-activated protein kinase activation by cytokines. Upon BCR cross-linking, IGBP1 transiently associates with tyrosine phosphorylated molecules, which in turn induce downstream signal transduction. Evidence suggests that IGBP1 association with PP2A may be involved in the rapamycin sensitive mTOR pathway. Formation of the IGBP1 and Midline ring finger protein complex has been identified as a prerequisite to pathogenesis of X-linked Optiz GBBB syndrome. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
